Drug Trial Radar · NCT03655678
A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia
Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
59
Actual
Start
Sep 14, 2018
Primary completion
Nov 13, 2025
Study completion Nov 13, 2025
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- Collaborators
- CRISPR Therapeutics
- First posted
- Aug 31, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in participans with transfusion-dependent β-thalassemia (TDT). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001.
Conditions
- Beta-Thalassemia
- Thalassemia
- Genetic Diseases, Inborn
- Hematologic Diseases
- Hemoglobinopathies
Interventions
CTX001Biological
Administered by IV infusion following myeloablative conditioning with busulfan
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving transfusion independence for at least 12 consecutive months (TI12)Time frame: From 60 days after last RBC transfusion up to 24 months post-CTX001 infusion]
- Proportion of participants with engraftment (first day of 3 consecutive measurements of absolute neutrophil count [ANC] ≥500/µL on three different days)Time frame: Within 42 days after CTX001 infusion
- Time to neutrophil and platelet engraftmentTime frame: Days post-infusion to engraftment
- Frequency and severity of collected adverse events (AEs)Time frame: Signing of informed consent through Month 24 visit
- Incidence of transplant-related mortality (TRM)Time frame: Baseline (pre-transfusion) to 100 days and 1 year post-CTX001 infusion
- All-cause mortalityTime frame: Signing of informed consent through Month 24 visit
Locations
14 sites in 5 countries. Site status is shown where the registry gives one.
Lucile Packard Children's Hospital
Palo Alto, California
Ann & Robert Lurie Children's Hospital of Chicago
Chicago, Illinois
Columbia University Medical Center (21+ years)
New York, New York
Columbia University Medical Center
New York, New York
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers
Nashville, Tennessee
The Hospital for Sick Children
Toronto, Canada
British Columbia Children's Hospital
Vancouver, Canada
Universitätsklinikum Düsseldorf Hospital Duesseldorf
Düsseldorf, Germany
Regensburg University Hospital, Clinic and Polyclinic for Paediatric and Adolescent Medicine
Regensburg, Germany
University Hospital Tübingen
Tübingen, Germany
Ospedale Pediatrico Bambino Gesù, IRCCS
Rome, Italy
Imperial College Healthcare NHS Trust, Hammersmith Hospital
London, United Kingdom
University College London Hospitals NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.